Bayer data for kidney disease hope finerenone sets up filingsBayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication Share XBayer data for kidney disease hope finerenone sets up filingshttps://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/
Janssen taps wearable tech in Invokana heart failure trialJanssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world Share XJanssen taps wearable tech in Invokana heart failure trialhttps://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/
FDA clears cardiovascular claim for J&J’s InvokanaJohnson & Johnson finally has some good news to report for its diabetes blockbuster Invokana, after the FDA Share XFDA clears cardiovascular claim for J&J’s Invokanahttps://pharmaphorum.com/news/fda-clears-cardiovascular-claim-for-jjs-invokana/
